family with sequence similarity 86, member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM86FP profile across patient tissues and cancer cell-line models. FAM86FP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, FAM86FP is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, FAM86FP RNA expression shows 15,636 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KICH, and TGCT as cancer lineages where FAM86FP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86FP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86FP survival associations across molecular data types. FAM86FP RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86FP RNA expression–survival associations across cancer types. High FAM86FP expression shows unfavorable associations in LGG, COAD and ACC, but favorable associations in BRCA, UVM and OV. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for FAM86FP RNA expression.
This table summarizes FAM86FP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86FP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86FP shows lower tumor expression in KICH, THCA, LUAD, KIRC and UCEC and higher tumor expression in CHOL. The KICH box plot shows higher FAM86FP RNA expression in normal versus tumor tissue (log2 FC = −0.940, t-test p < 0.001).
This table shows molecular features associated with FAM86FP in patient tissues and cancer cell lines. In patient samples, FAM86FP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
